-

VALERIO THERAPEUTICS: List of the Board Members Positions Held in Other Companies as of March 19, 2025

PARIS--(BUSINESS WIRE)--Regulatory News:

VALERIO THERAPEUTICS (Paris:ALVIO):

 Name of Director

Other offices and functions

 

Julien MIARA

Chief Executive Officer and Director

 

  • Managing Director at Invus
  • Director of Sensorion
  • Director of Versity

 

Jacques MALLET

Director and Chairman of the Board

 

  • Chairman of Gamma-X Corporate Advisory
  • Director of Technoflex
  • Director of the Fournier Majoie Foundation

 

FINANCIERE DE LA MONTAGNE, represented by Nicolas TREBOUTA

Director

 

  • Manager of SARL Financière de la Montagne
  • Manager of SCI Fleurus Immobilier
  • Chairman of SAS Dragon 8
  • Managing partner of SC Financière des Associés
  • Chairman of the Supervisory Board of SCA Chevrillon & Associés
  • Manager of EARL Ferme de Bissy
  • Managing partner of SC Valois
  • Co-manager of SC Aster
  • Managing partner of SCI du Chardonnet

 

Bryan GIRAUDO

Director

 

  • Chief Operating Officer and Chief Financial Officer of Gossamer Bio Inc
  • Director of Protagonist Therapeutics
  • Senior Managing Director at Leerink Partners

Antoine BAROUKY

Chief Operating Officer and Director

  • Chairman & CEO of MAAsiRNA
  • Chairman & CEO of AB Global Strategy
  • Venture Partner at Invus

 

Shefali AGARWAL

Director

 

  • Member of the Board of Directors of ITB Med (unlisted)
  • Member of the Board of Directors of Gritstone Bio (Nasdaq: GTRS)
  • Member of the Board of Directors of Fate Therapeutics (Nasdaq: FATE)

VALERIO THERAPEUTICS
Société anonyme à conseil d’administration au capital social de 21.610.998,20 euros
Siège social : 49 boulevard du Général Martial Valin, 75015 Paris 410 910 095 R.C.S. Paris

Contacts

VALERIO THERAPEUTICS

VALERIO THERAPEUTICS

BOURSE:ALVIO

Release Versions

Contacts

VALERIO THERAPEUTICS

More News From VALERIO THERAPEUTICS

Valerio Therapeutics Publishes Its 2025 Annual Results and Annual Financial Report, and Confirms the Strategic Transformation of Its Operating Model

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 – ALVIO), a biotechnology company specializing in the development of technology platforms dedicated to the targeted delivery of innovative therapies (the “Company”), today announces the publication of its annual results and annual financial report for the 2025 financial year, [available on its website under the “Financial Information” section], and outlines the key pillars of its strategic roadmap. “2025 was...

Valerio Therapeutics Announces the Appointment of Professor Eric Vivier as Observer to Its Board of Directors

PARIS--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (“Valerio Therapeutics” or the “Company”) (Euronext Growth Paris: ALVIO) announces the appointment of Professor Eric Vivier as an Observer to its Board of Directors. His nomination as a Director will be submitted to shareholders at the Company’s next general meeting. Professor Eric Vivier works within Aix Marseille University and Assistance Publique-Hôpitaux de Marseille (AP-HM) and is also a professor at École Polytechnique (X). He...

Valerio Therapeutics: Postponement of 2024 Annual Financial Report Publication and the Approval of Financial Statements

PARIS--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) (the “Company”) announces the postponement of the publication of its 2024 annual financial report, initially scheduled for April 30, 2025, as well as the finalization and approval of its statutory and consolidated financial statements for 2024. The Company is facing significant difficulties in accessing the accounting records of its U.S. subsidiary, Valerio Therapeutics Inc. Although the assets rel...
Back to Newsroom